Clinical observation of pneumomediastinum in a case of severe COVID-19-associated pneumonia in a teenager

Author:

Knizhnikova E. V.1,Evseeva G. P.2,Cherezov S. A.3,Adlivankina T. M.3,Telepneva R. S.2,Suprun S. V.2,Lebedko O. A.2

Affiliation:

1. Khabarovsk Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Maternity and Childhood Protection; City Clinical Hospital named after professor A.M. Voino-Yasenetsky

2. Khabarovsk Branch of Far Eastern Scientific Center of Physiology and Pathology of Respiration – Research Institute of Maternity and Childhood Protection

3. City Clinical Hospital named after professor A.M. Voino-Yasenetsky

Abstract

Aim. Demonstration of the clinical case of pneumomediastinum in a teenager with severe COVID-19- associated pneumonia.Materials and methods. The clinical case of spontaneous pneumomediastinum was presented, which was a complication of the severe course of COVID-19 pneumonia in a teenager.Results. Patient Ch., 15 years old, with obesity of the 1st degree, was admitted to the hospital of infectious diseases for patients with a COVID-19 on the 7th day of the illness in a severe condition and had complaints of an increase in body temperature to 40ºC, pronounced cough and weakness, dyspnea when walking and at rest. The PCR test for SARS-CoV-2 gave a positive result. Multispiral computed tomography showed polysegmental interstitial lesion of both lungs, which had multiple areas of “ground glass”, signs of pneumomediastinum, subcutaneous emphysema of the upper third of the chest, left-sided pleural effusion. The volume of lung tissue lesion was 50% on the right and 85% on the left. The positive effect of treatment was not observed after 2-3 days in the hospital. The condition of heavy severity continued due to intoxication syndrome, respiratory failure, inflammatory changes in lung tissue syndrome. In this regard, the patient was injected intravenously with tocilizumab (Actemra®) 400 mg. The child was released on the 20th day of hospitalization with a positive clinical effect.Conclusion. The above clinical case demonstrates that in children a novel coronavirus infection can occur not only in severe form, but also with the possible development of complications in the form of pneumomediastinum and low effectiveness of antibacterial and antiviral therapy, which required the use of humanized monoclonal antibodies (tocilizumab).

Publisher

Far Eastern Scientific Center Of Physiology and Pathology of Respiration

Subject

General Medicine

Reference14 articles.

1. Alexandrovich Yu.S., Alekseeva E.I., Bakradze M.D., Baranov A.A., Batysheva T.T., Vashakmadze N.D., Vershinina M.G., Vishneva E.A., Glazyrina A.A., Gordeeva O.B., Dyakonova E.Yu., Zholobova Е.S., Zabolotsky D.V., Zvereva N.N., Zelenkova I.V., Ivanov D.O., Kaytukova E.V., Karkashadze G.A., Konovalov I.V., Kruchko D.S., Kulichenko T.V., Kurbanova S.K., Levina Y.G., Lobzin Yu.V., Mazankova L.N., Margieva T.V., Namazova-Baranova L.S., Novikova Yu.Yu., Ovsyannikov D.Yu., Petryaykina E.E., Petrenko Yu.V., Petrova N.V., Prometnoy D.V., Pshenisov K.V., Revunenkov G.V., Rtishchev A.Yu., Rusinova D.S., Sayfullin M.A., Sayfullin R.F., Selimzyanova L.R., Tatochenko V.K., Tepaev R.F., Uskov A.N., Fedoseenko M.V., Fisenko A.P., Khar’kin A.V., Efendieva K.E., Yakovlev A.V. [Clinical Features and Management of the Disease Caused by New Coronaviral Infection (COVID-19) in Children. Version 2.]. Pediatric pharmacology 2020; 17(3):187−212 (in Russian). https://doi.org/10.15690/pf.v17i3.2123

2. Evseeva G.P., Telepneva R.S., Knizhnikova E.V., Suprun S.V., Pichugina S.V., Yakovlev E.I., Galyant O.I., Kozlov V.K., Lebed’ko O.A. [COVID-19 in pediatric population]. Bûlleten' fiziologii I patologii dyhaniâ = Bulletin Physiology and Pathology of Respiration 2021; (80):100–114 (in Russian). https://doi.org/10.36604/1998-5029-2021-80-100-114

3. Shekerdemian L.S., Mahmood N.R., Wolfe K.K., Riggs B.J., Ross C.E., McKiernan C.A., Heidemann S.M., Kleinman L.C., Sen A.I., Hall M.W., Priestley M.A., McGuire J.K., Boukas K., Sharron M.P., Burns J.P. Characteristics and Outcomes of Children With Coronavirus Disease 2019(COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatrics 2020; 174(9):868–873. https://doi.org/10.1001/jamapediatrics.2020.1948

4. Dong Y., Mo X., Hu Y., Qi X., Jiang F., Jiang Z., Tong S. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; 145(6):e20200702. https://doi.org/10.1542/peds.2020-0702

5. Mazankova L.N., Osmanov I.M., Samitova E.R., Malakhov A.B., Koroid V.V., Nedostoev А.A., Kaurova E.P., Kuznetsova T.A., Kulichkina O.S., Loban N.V. A teenager with a severe form of COVID-19. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 2020; 65(5):58−65 (in Russian). https://doi.org/10.21508/1027-4065-2020-65-5-58-65

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3